Moogene Medi Co., Ltd. (XKON:322970)

Market Cap	29.95B +33.6%
Revenue (ttm)	12.95M -87.2%
Net Income	-2.08B
EPS	-332.00
Shares Out	10.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,789
Average Volume	8,448
Open	2,910.00
Previous Close	2,985.00
Day's Range	2,755.00 - 2,980.00
52-Week Range	1,720.00 - 3,790.00
Beta	-0.03
RSI	59.36
Earnings Date	n/a

About Moogene Medi

Moogene Medi Co., Ltd. develops nanobiotechnology-based drug delivery systems. It develops lipid nanoparticle (LNP) materials for pharmaceutical protein delivery; RNP (sgRNA+ CRISPR Cas9)-encapsulated LNP for gene therapy; novel therapy for colorectal or pancreatic cancer with anticancer drug resistance due to genetic mutation by using RNP-encapsulated LNP; and topical treatment for androgenic alopecia therapy. The company was founded in 2016 and is headquartered in Hanam-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 322970

Financial Performance

In 2019, Moogene Medi's revenue was 12.95 million, a decrease of -87.17% compared to the previous year's 100.95 million. Losses were -2.08 billion, 41.4% more than in 2018.